Evaluation of CCNU and misonidazole in the treatment of advanced colorectal cancer.
Eighteen adult colorectal cancer patients, previously untreated with systemic chemotherapy, were given CCNU and MISO. One patient had an excellent partial response of pulmonary metastases, but the overall response rate was only 6%. Gastrointestinal toxicity was modest, hematologic toxicity was similar to what would have been predicted for CCNU alone, and there was no neurotoxicity detected. This Phase II study demonstrates that these two agents can be administered safely, but have no advantage over CCNU alone.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage* / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality
D008130:Lomustine; D008920:Misonidazole